Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reported a routine share buyback under its non‑discretionary agreement with BNP Paribas SA. On 03 November 2025, the company purchased 170,500 ordinary shares of 31¼ pence each at a lowest price 1,758.50p, highest price 1,782.00p, and volume‑weighted average price (VWAP) 1,769.85p. The shares will be held as Treasury shares and form part of the existing buyback programme announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 7,474,000 ordinary shares. After the latest transaction, GSK holds 254,938,844 shares in treasury and has 4,060,484,755 ordinary shares in issue (excluding treasury). The total voting rights are 4,060,484,755, and the percentage of voting rights attributable to treasury shares is 6.28%.
GSK plc reported a routine share buyback under its non‑discretionary agreement with BNP Paribas SA. On 03 November 2025, the company purchased 170,500 ordinary shares of 31¼ pence each at a lowest price 1,758.50p, highest price 1,782.00p, and volume‑weighted average price (VWAP) 1,769.85p. The shares will be held as Treasury shares and form part of the existing buyback programme announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 7,474,000 ordinary shares. After the latest transaction, GSK holds 254,938,844 shares in treasury and has 4,060,484,755 ordinary shares in issue (excluding treasury). The total voting rights are 4,060,484,755, and the percentage of voting rights attributable to treasury shares is 6.28%.
GSK plc reported its monthly total voting rights and capital. As at 31 October 2025, the company had 4,315,423,599 Ordinary Shares of 31 ¼ pence each in issue, of which 254,768,344 were held in treasury. The resulting total number of voting rights is 4,060,655,255.
Shareholders may use this voting rights figure as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.
GSK plc reported its monthly total voting rights and capital. As at 31 October 2025, the company had 4,315,423,599 Ordinary Shares of 31 ¼ pence each in issue, of which 254,768,344 were held in treasury. The resulting total number of voting rights is 4,060,655,255.
Shareholders may use this voting rights figure as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.
GSK plc reported a share buyback transaction executed via BNP Paribas SA, purchasing 175,000 ordinary shares on 31 October 2025. Prices ranged from 1,760.00p to 1,791.50p with a volume‑weighted average price of 1,780.09p. The shares will be held as Treasury shares as part of the Company’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025. Since 30 September 2025, the Company has purchased 7,303,500 shares.
After this purchase, GSK holds 254,768,344 shares in treasury and has 4,060,655,255 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,060,655,255, and treasury shares represent 6.27% of voting rights. The filing also provides a venue‑level breakdown and individual trade details for trades on XLON, CHIX and BATE.
GSK plc reported a share buyback transaction executed via BNP Paribas SA, purchasing 175,000 ordinary shares on 31 October 2025. Prices ranged from 1,760.00p to 1,791.50p with a volume‑weighted average price of 1,780.09p. The shares will be held as Treasury shares as part of the Company’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025. Since 30 September 2025, the Company has purchased 7,303,500 shares.
After this purchase, GSK holds 254,768,344 shares in treasury and has 4,060,655,255 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,060,655,255, and treasury shares represent 6.27% of voting rights. The filing also provides a venue‑level breakdown and individual trade details for trades on XLON, CHIX and BATE.
GSK plc reported a daily share repurchase under its existing buyback programme. On 30 October 2025, the company bought 180,000 ordinary shares at prices between 1,726.50p and 1,780.00p, with a volume-weighted average price of 1,756.23p. The shares will be held as treasury shares.
Since 30 September 2025, GSK has purchased 7,128,500 ordinary shares. Following this transaction, GSK holds 254,593,344 ordinary shares in treasury and has 4,060,827,442 ordinary shares in issue (excluding treasury shares). The total number of voting rights is 4,060,827,442, and the percentage of voting rights attributable to treasury shares is 6.27%.
GSK plc reported a daily share repurchase under its existing buyback programme. On 30 October 2025, the company bought 180,000 ordinary shares at prices between 1,726.50p and 1,780.00p, with a volume-weighted average price of 1,756.23p. The shares will be held as treasury shares.
Since 30 September 2025, GSK has purchased 7,128,500 ordinary shares. Following this transaction, GSK holds 254,593,344 ordinary shares in treasury and has 4,060,827,442 ordinary shares in issue (excluding treasury shares). The total number of voting rights is 4,060,827,442, and the percentage of voting rights attributable to treasury shares is 6.27%.
GSK plc reported dealings by two senior executives. Regis Simard sold 37,000 Ordinary Shares at £16.8395 per share, and Deborah Waterhouse sold 120,000 Ordinary Shares at £16.8865 per share. Both transactions were single trades executed on the London Stock Exchange on 2025-10-29.
GSK plc repurchased 180,000 ordinary shares on 29 October 2025 under its existing buyback programme via BNP Paribas SA. The shares were bought between 1,669.50p and 1,761.00p at a volume‑weighted average price of 1,720.61p and will be held as treasury shares.
Since 30 September 2025, the company has purchased 6,948,500 shares. After this transaction, GSK holds 254,413,344 shares in treasury and has 4,061,007,442 shares in issue (excluding treasury). Total voting rights are 4,061,007,442, and treasury-held voting rights represent 6.26%. Venue-level VWAPs were 1,747.19p (BATE), 1,731.86p (CHIX), and 1,718.16p (XLON).
GSK plc repurchased 180,000 ordinary shares on 29 October 2025 under its existing buyback programme via BNP Paribas SA. The shares were bought between 1,669.50p and 1,761.00p at a volume‑weighted average price of 1,720.61p and will be held as treasury shares.
Since 30 September 2025, the company has purchased 6,948,500 shares. After this transaction, GSK holds 254,413,344 shares in treasury and has 4,061,007,442 shares in issue (excluding treasury). Total voting rights are 4,061,007,442, and treasury-held voting rights represent 6.26%. Venue-level VWAPs were 1,747.19p (BATE), 1,731.86p (CHIX), and 1,718.16p (XLON).
GSK plc reported a routine share repurchase under its existing buyback programme. On 28 October 2025, the company bought 320,000 ordinary shares at prices between 1,634.00p and 1,655.00p, with a volume‑weighted average price of 1,644.29p. The shares will be held as treasury shares and the purchases were executed by BNP Paribas SA under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 6,768,500 shares. Following this transaction, GSK holds 254,233,344 shares in treasury and has 4,061,187,442 shares in issue (excluding treasury shares), which is also the total number of voting rights. The percentage of voting rights attributable to treasury shares is 6.26%. Aggregated venue volumes for the day were BATE 44,453, CHIX 44,604, and XLON 230,943.
GSK plc reported a routine share repurchase under its existing buyback programme. On 28 October 2025, the company bought 320,000 ordinary shares at prices between 1,634.00p and 1,655.00p, with a volume‑weighted average price of 1,644.29p. The shares will be held as treasury shares and the purchases were executed by BNP Paribas SA under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 6,768,500 shares. Following this transaction, GSK holds 254,233,344 shares in treasury and has 4,061,187,442 shares in issue (excluding treasury shares), which is also the total number of voting rights. The percentage of voting rights attributable to treasury shares is 6.26%. Aggregated venue volumes for the day were BATE 44,453, CHIX 44,604, and XLON 230,943.
GSK reported a strong Q3, with turnover of £8,547 million (+8% CER) and Core EPS of 55.0p (+14% CER). Total operating profit and Total EPS rose by over 100%, helped by lower Significant legal expenses, lower CCL charges and higher other operating income. Cash generated from operations was £2,520 million and free cash flow was £1,246 million.
Growth was broad-based: Specialty Medicines £3,409 million (+16% CER) led by HIV (£1,944 million, +12% CER) and Oncology (£511 million, +39% CER); Vaccines £2,678 million (+2% CER) with Shingrix £830 million (+13% CER) and Arexvy £251 million (+36% CER); General Medicines £2,460 million (+4% CER) with Trelegy £736 million (+25% CER). GSK upgraded 2025 guidance at CER to turnover growth of 6–7%, Core operating profit growth of 9–11%, and Core EPS growth of 10–12%. The company declared a 16p Q3 dividend (64p expected for 2025) and has spent £1.1 billion YTD toward its £2 billion share buyback.
GSK reported a strong Q3, with turnover of £8,547 million (+8% CER) and Core EPS of 55.0p (+14% CER). Total operating profit and Total EPS rose by over 100%, helped by lower Significant legal expenses, lower CCL charges and higher other operating income. Cash generated from operations was £2,520 million and free cash flow was £1,246 million.
Growth was broad-based: Specialty Medicines £3,409 million (+16% CER) led by HIV (£1,944 million, +12% CER) and Oncology (£511 million, +39% CER); Vaccines £2,678 million (+2% CER) with Shingrix £830 million (+13% CER) and Arexvy £251 million (+36% CER); General Medicines £2,460 million (+4% CER) with Trelegy £736 million (+25% CER). GSK upgraded 2025 guidance at CER to turnover growth of 6–7%, Core operating profit growth of 9–11%, and Core EPS growth of 10–12%. The company declared a 16p Q3 dividend (64p expected for 2025) and has spent £1.1 billion YTD toward its £2 billion share buyback.
GSK plc reported a transaction in its own shares as part of its existing buyback programme. On 27 October 2025, acting through BNP Paribas SA, the company purchased 166,000 ordinary shares at prices between 1,632.50p and 1,645.00p, with a volume‑weighted average price of 1,637.64p. The shares will be held as Treasury shares.
Since 30 September 2025, GSK has purchased 6,448,500 ordinary shares under the programme. Following this purchase, GSK holds 253,913,344 shares in treasury and has 4,061,507,442 ordinary shares in issue (excluding treasury shares). The total number of voting rights is 4,061,507,442, and the percentage of voting rights attributable to treasury shares is 6.25%.
The filing also lists aggregated venue data (XLON, CHIX, BATE) for the day’s trades and provides media and investor relations contacts.
GSK plc reported a transaction in its own shares as part of its existing buyback programme. On 27 October 2025, acting through BNP Paribas SA, the company purchased 166,000 ordinary shares at prices between 1,632.50p and 1,645.00p, with a volume‑weighted average price of 1,637.64p. The shares will be held as Treasury shares.
Since 30 September 2025, GSK has purchased 6,448,500 ordinary shares under the programme. Following this purchase, GSK holds 253,913,344 shares in treasury and has 4,061,507,442 ordinary shares in issue (excluding treasury shares). The total number of voting rights is 4,061,507,442, and the percentage of voting rights attributable to treasury shares is 6.25%.
The filing also lists aggregated venue data (XLON, CHIX, BATE) for the day’s trades and provides media and investor relations contacts.
GSK plc reported that its B7-H3–targeted antibody-drug conjugate, GSK5764227 (GSK'227), received Orphan Drug Designation from the European Medicines Agency for treating pulmonary neuroendocrine carcinoma, a group that includes small‑cell lung cancer. The designation is based on preliminary phase I ARTEMIS-001 data showing durable responses in extensive‑stage SCLC.
This marks the fourth regulatory designation for GSK'227. The program previously secured EMA PRIME for relapsed or refractory ES‑SCLC and two US FDA Breakthrough Therapy Designations for relapsed or refractory ES‑SCLC and late‑line relapsed or refractory osteosarcoma. GSK began a global phase III trial in relapsed ES‑SCLC in August 2025.
SCLC remains a high‑need cancer, with an estimated 250,000 diagnoses and about 200,000 deaths annually worldwide. GSK holds exclusive worldwide rights to GSK'227 outside mainland China, Hong Kong, Macau, and Taiwan.
GSK plc reported that its B7-H3–targeted antibody-drug conjugate, GSK5764227 (GSK'227), received Orphan Drug Designation from the European Medicines Agency for treating pulmonary neuroendocrine carcinoma, a group that includes small‑cell lung cancer. The designation is based on preliminary phase I ARTEMIS-001 data showing durable responses in extensive‑stage SCLC.
This marks the fourth regulatory designation for GSK'227. The program previously secured EMA PRIME for relapsed or refractory ES‑SCLC and two US FDA Breakthrough Therapy Designations for relapsed or refractory ES‑SCLC and late‑line relapsed or refractory osteosarcoma. GSK began a global phase III trial in relapsed ES‑SCLC in August 2025.
SCLC remains a high‑need cancer, with an estimated 250,000 diagnoses and about 200,000 deaths annually worldwide. GSK holds exclusive worldwide rights to GSK'227 outside mainland China, Hong Kong, Macau, and Taiwan.